Global epidemiology of non-influenza RNA respiratory viruses : data gaps and a growing need for surveillance
Copyright © 2017 Elsevier Ltd. All rights reserved..
Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.
| Errataetall: |
ErratumIn: Lancet Infect Dis. 2017 Jul;17(7):689. - PMID 28653628 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 17(2017), 10 vom: 03. Okt., Seite e320-e326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Julian W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.10.2017 Date Revised 13.11.2023 published: Print-Electronic ErratumIn: Lancet Infect Dis. 2017 Jul;17(7):689. - PMID 28653628 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(17)30238-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271434430 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271434430 | ||
| 003 | DE-627 | ||
| 005 | 20231224232709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(17)30238-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0904.xml |
| 035 | |a (DE-627)NLM271434430 | ||
| 035 | |a (NLM)28457597 | ||
| 035 | |a (PII)S1473-3099(17)30238-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Julian W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global epidemiology of non-influenza RNA respiratory viruses |b data gaps and a growing need for surveillance |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2017 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Lancet Infect Dis. 2017 Jul;17(7):689. - PMID 28653628 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Lam, Tommy T |e verfasserin |4 aut | |
| 700 | 1 | |a Zaraket, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Lipkin, W Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Drews, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Hatchette, Todd F |e verfasserin |4 aut | |
| 700 | 1 | |a Heraud, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P |e verfasserin |4 aut | |
| 700 | 0 | |a INSPIRE investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Ashta Mary |e investigator |4 oth | |
| 700 | 1 | |a Baraket, Amal |e investigator |4 oth | |
| 700 | 1 | |a Bialasiewicz, Seweryn |e investigator |4 oth | |
| 700 | 1 | |a Caniza, Miguela A |e investigator |4 oth | |
| 700 | 1 | |a Chan, Paul Ks |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Cheryl |e investigator |4 oth | |
| 700 | 1 | |a Corriveau, André |e investigator |4 oth | |
| 700 | 1 | |a Cowling, Benjamin J |e investigator |4 oth | |
| 700 | 1 | |a Drews, Steven J |e investigator |4 oth | |
| 700 | 1 | |a Echavarria, Marcela |e investigator |4 oth | |
| 700 | 1 | |a Fouchier, Ron |e investigator |4 oth | |
| 700 | 1 | |a Fraaij, Pieter LA |e investigator |4 oth | |
| 700 | 1 | |a Hachette, Todd F |e investigator |4 oth | |
| 700 | 1 | |a Heraud, Jean-Michel |e investigator |4 oth | |
| 700 | 1 | |a Jalal, Hamid |e investigator |4 oth | |
| 700 | 1 | |a Jennings, Lance |e investigator |4 oth | |
| 700 | 1 | |a Kabanda, Alice |e investigator |4 oth | |
| 700 | 1 | |a Kadjo, Herve A |e investigator |4 oth | |
| 700 | 1 | |a Khanani, Mohammed Rafiq |e investigator |4 oth | |
| 700 | 1 | |a Koay, Evelyn Sc |e investigator |4 oth | |
| 700 | 1 | |a Koopmans, Marion P |e investigator |4 oth | |
| 700 | 1 | |a Krajden, Mel |e investigator |4 oth | |
| 700 | 1 | |a Lam, Tommy T |e investigator |4 oth | |
| 700 | 1 | |a Lee, Hong Kai |e investigator |4 oth | |
| 700 | 1 | |a Lipkin, W Ian |e investigator |4 oth | |
| 700 | 1 | |a Lutwama, Julius |e investigator |4 oth | |
| 700 | 1 | |a Marchant, David |e investigator |4 oth | |
| 700 | 1 | |a Nishimura, Hidekazu |e investigator |4 oth | |
| 700 | 1 | |a Nymadawa, Pagbajabyn |e investigator |4 oth | |
| 700 | 1 | |a Pinsky, Benjamin A |e investigator |4 oth | |
| 700 | 1 | |a Rughooputh, Sanjiv |e investigator |4 oth | |
| 700 | 1 | |a Rukelibuga, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Saiyed, Taslimarif |e investigator |4 oth | |
| 700 | 1 | |a Shet, Anita |e investigator |4 oth | |
| 700 | 1 | |a Sloots, Theo |e investigator |4 oth | |
| 700 | 1 | |a Tamfum, Jj Muyembe |e investigator |4 oth | |
| 700 | 1 | |a Tang, Julian W |e investigator |4 oth | |
| 700 | 1 | |a Tempia, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Tozer, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Treurnicht, Florette |e investigator |4 oth | |
| 700 | 1 | |a Waris, Matti |e investigator |4 oth | |
| 700 | 1 | |a Watanabe, Aripuana |e investigator |4 oth | |
| 700 | 1 | |a Wemakoy, Emile Okitolonda |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 17(2017), 10 vom: 03. Okt., Seite e320-e326 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:10 |g day:03 |g month:10 |g pages:e320-e326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(17)30238-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 10 |b 03 |c 10 |h e320-e326 | ||